Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1interventionalRules rewrite

Phase 1: testing NNC9836-0001 for Diabetes Mellitus, Type 2

The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or dummy treatment (placebo).

Official registry: https://clinicaltrials.gov/study/NCT07896109 · Novo Nordisk A/S · enrollment listed as 121

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are NNC9836-0001, or Placebo (NaCl). The registry lists allocation as randomized. The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D).

They plan to enroll about 121 people at Neuss. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 1 Randomised, Double-blinded, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of NNC9836-0001 Administered to Healthy Participants and Participants With Type 2 Diabetes

Interventions: NNC9836-0001, Placebo (NaCl)

Primary outcome (registry wording): Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)

Who it is for (from inclusion criteria)

  • Ages 25 Years to 69 Years
  • Male or female (sex assigned at birth, inclusive of all gender identities)
  • Metabolically healthy participants with overweight or mild obesity:
  • Body Mass Index (body-mass index (BMI)) 25 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator
  • Participants with type 2 diabetes:
  • body-mass index (BMI) at screening: body-mass index (BMI) 27 to 39.9 kg/m\^2 (both inclusive)
  • Diagnosed with T2D greater than equal to (≥) 180 days before screening

Public study contact (from the registry)

Novo Nordisk

(+1) 866-867-7178

clinicaltrials@novonordisk.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseSan Antonio, Texas
Not a traditional drug phase: testing Dapagliflozin for Diabetes Mellitus, Type 2

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

NCT02969798 · Official ClinicalTrials.gov record · The University of Texas Health Science Center at San Antonio

FAQ about this NCT record

Is NCT07896109 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07896109?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07896109?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary